BioPharma Resources

Drug Trial Radar · NCT04843449

Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

A Phase I, Open Label, Drug-drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Apr 4, 2021

Primary completion

May 6, 2021

Study completion May 14, 2021

Sponsor

Sponsor type
Industry
First posted
Apr 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effects of itraconazole (a strong inhibitor of cytochrome P450 3A (CYP3A)) and rifampicin (a strong inducer of CYP3A) on the pharmacokinetics of ASC40 in healthy volunteers.

Conditions

  • Healthy

Interventions

  • ASC40Drug

    Oral tablets

  • ItraconazoleDrug

    Oral capsules

  • rifampicinDrug

    Oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC of ASC40Time frame: Up to 24 days
  2. Cmax of ASC40Time frame: Up to 24 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hunan provincial people's hospital

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.